FindTrial
Sign In

Clinical observation of Traditional Chinese medicine and Western medicine in treating primary liver cancer patients

Clinical observation of Traditional Chinese medicine and Western medicine in treating primary liver cancer patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100005449
Enrollment
Unknown
Registered
2021-12-26
Start date
2017-01-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

integrative treatment group:Traditional Chinese medicine and Western medicine
control:Western medicine

Sponsors

the Fifth Medical Center of Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) patients ( BCLC class A, B or C ) with a confirmed first diagnosis of HCC; (2) age =18 and =80 years; (3) Western medicine treatment measures have been taken; (4) following time =2 years

Exclusion criteria

Exclusion criteria: (1) patients with history of abnormal bleeding tendency; (2) patients with severe acute or chronic disease (myocardial infarction, stroke, diabetes and uncontrolled infection, et al); (3) tumor metastases or portal invasion or macrovascular invasion confirmed; (4) women who were pregnant or breast feeding; (5) patients with history of drug abuse or psychiatric disorders.

Design outcomes

Primary

MeasureTime frame
Recurrence-free survival;—

Secondary

MeasureTime frame
safety;overall survival;—

Countries

China

Contacts

Public Contactwangruilin

the Fifth Medical Center of Chinese PLA General Hospital

wrl7905@163.com13811050593

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026